Preemptive Ganciclovir Therapy in Cytomegalovirus-Seropositive Renal Transplants Recipients
David J. Conti, MD;
Brian M. Freed, PhD;
T. Paul Singh, MD;
Michael Gallichio, MD;
Scott A. Gruber, MD, PhD;
Neil Lempert, MD
Arch Surg. 1995;130(11):1217-1222.
Abstract
Objective
To evaluate the efficacy, safety, and cost of preemptive ganciclovir therapy in cytomegalovirus (CMV)-seropositive renal transplant recipients treated with antilymphocyte antibody (ALA) preparations.
Design and Setting
A prospective, randomized trial at a 650-bed tertiary medical center hospital.
Patients
Forty consecutive CMV-seropositive renal allograft recipients who underwent transplantation between January 1992 and January 1994 and were treated with ALA for induction immunosuppression or acute rejection therapy.
Main Outcome Measures
The incidence and severity of CMV disease, length of hospitalization, and patient and allograft survival.
Intervention
Cytomegalovirus infection prophylaxis by use of intravenous ganciclovir during ALA therapy was administered to 22 patients (group 1) and the results were compared with those obtained in 18 control patients who did not receive prophylaxis for CMV disease (group 2).
Results
Preemptive ganciclovir therapy significantly reduced the incidence of CMV disease (P<.05) in CMV-seropositive renal transplant patients who were treated with ALA and was well tolerated. In addition, the cost of prophylactic therapy was offset by the decreased length of hospitalization observed in patients in group 1.
Conclusion
Preemptive ganciclovir therapy provides a cost-effective approach toward significantly improving the outcome of renal transplantation in CMV-seropositive patients treated with ALA.
(Arch Surg. 1995;130:1217-1222)
Author Affiliations
From the Department of Surgery, Section of Transplantation, Albany Medical College, Albany, NY.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients
Kalil and Stoner
ANN INTERN MED 2006;144:457-457.
FULL TEXT
Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
Singh and Wagener
ANN INTERN MED 2006;144:456-457.
FULL TEXT
Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients
Kalil et al.
ANN INTERN MED 2005;143:870-880.
ABSTRACT
| FULL TEXT
Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy
Wang et al.
Ann. Thorac. Surg. 2004;78:267-272.
ABSTRACT
| FULL TEXT
{beta}-Herpesvirus Challenges in the Transplant Recipient
Ljungman
The Journal of Infectious Disease 2002;186:S99-S109.
ABSTRACT
| FULL TEXT
Distinguishing Cytomegalovirus (CMV) Infection and Disease with CMV Nucleic Acid Assays
Caliendo et al.
J. Clin. Microbiol. 2002;40:1581-1586.
ABSTRACT
| FULL TEXT
Management of Cytomegalovirus Infection and Disease after Solid-Organ Transplantation
van der Bij and Speich
Clinical Infectious Diseases 2001;33:S32-S37.
ABSTRACT
| FULL TEXT
Preemptive Therapy Versus Universal Prophylaxis with Ganciclovir for Cytomegalovirus in Solid Organ Transplant Recipients
Singh
Clinical Infectious Diseases 2001;32:742-751.
ABSTRACT
| FULL TEXT
Prevention of Cytomegalovirus Disease in Recipients of Solid-Organ Transplants
Snydman and Paya
Clinical Infectious Diseases 2001;32:596-603.
ABSTRACT
| FULL TEXT
Management of herpes virus infections following transplantation
J Antimicrob Chemother 2000;45:729-748.
FULL TEXT
New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients
Sia and Patel
Clin. Microbiol. Rev. 2000;13:83-121.
ABSTRACT
| FULL TEXT
|
